Molecular Biology Faculty
Lewis Thomas Lab, 110
Lab (609) 258-2914
Infectious diseases account for at least 15 million deaths each year - almost a quarter of all human deaths worldwide. Against a constant background of established infections, epidemics of new and old infectious diseases periodically emerge, greatly magnifying the global burden of infections. Many pathogens causing disease in humans exhibit nearly unique human tropism, posing additional challenges for studying host-pathogen interaction and for efficiently testing anti-microbial intervention strategies. Humanized mice, i.e. mice expressing human genes or containing human tissues, have emerged as powerful systems to model human infections in vivo. We have and continue to construct humanized hosts genetically or via xenotransplantation to analyze previously intractable human (hepatotropic) pathogens. These systems offer unprecedented opportunities to effectively study host-pathogen interactions in vivo and to preclinically evaluate drug and vaccine candidates.
The research of my lab focuses on immune responses and pathogenesis to human pathogens infecting the liver, including hepatitis B (HBV) and C viruses (HCV), yellow fever and Dengue viruses and plasmodial parasites. My group combines tissue engineering, molecular virology/pathogenesis, and animal construction, to create and apply innovative technologies for the study and intervention of human hepatotropic infections.
Determinants of interspecies tropism of human hepatotropic pathogens
Many of these pathogens display unique human tropism, and the development of novel intervention strategies has been hampered by the lack of robust, cost effective and predictive models that accurately reproduce the hallmarks of human infections. While rodents and non-human primates have been employed in biomedical research and drug/vaccine development, they often do not yield reliable pre-clinical results that translate into effective human treatments. Two important factors contribute to this failure: on the microbial side, surrogate pathogens often differ significantly from highly restricted human counterparts; on the host side, the immune correlates of protection in non-human mammalian species often diverge from human responses.
My group uses several independent but possibly complementary approaches to overcome current species barriers and generate a small animal model for microbial pathogenesis: 1. Adaptation of microbial genomes to infect hepatocytes of non-human origin (mice and/or smaller non-human primates). 2. Humanization of the mouse liver and immune system by transplanting human hematopoietic stem cells and hepatocytes into a single murine recipient, thus allowing studies of pathology, immune correlates, and mechanisms of pathogen persistence. 3. Genetic host adaptation to create inbred murine models for viral pathogens. The latter approach encompasses systematic screens to identify and overcome additional species restrictions. We apply genome-engineering techniques to render the murine host environment more conducive to infections with the respective human pathogens.
Pathogenesis of viral hepatitis
Five distinct viruses, hepatitis A, B, C, delta and E viruses, are known to cause hepatitis in humans. HAV and HEV infections cause by-and-large acute, spontaneously resolving infections. In contrast, in excess of 500 million people are persistently infected with HBV/HDV and HCV. Chronic carriers are at risk of developing severe liver disease, including fibrosis, cirrhosis and hepatocellular carcinoma. An effective vaccine has been developed to prevent HBV infection, however, established infections are currently incurable and require life-long suppression with antiviral drugs. HBV pathogenesis is frequently exacerbated by co-infection with HDV. HDV is generally considered to be a subviral satellite because it can propagate only in the presence of the HBV. HBV persist in host cells as covalently closed circular DNA (cccDNA). Mechanisms of HBV persistence are incompletely understood.
Likewise, HCV has a high propensity of establishing chronic infections in human. A protective vaccine for HCV has not yet been developed. Current treatment - although projected to be improving considerably in the future - is only partially effective and plagued with side-effects but can result in complete elimination of the virus. We aim to shed light on the mechanisms governing HCV persistence.
Molecular characterization of plasmodial dormancy
Malaria accounts for more than 2% of all human deaths world-wide. A call was made for the global elimination of malaria, involving the eradication of all human malaria parasite species. Malaria is an arthropod borne infection caused in humans by five different species of Plasmodium, of which primarily P. vivax (Pv) – responsible for 70-80 million infections annually - has a high propensity for developing dormant stages - hypnozoites. In any attempt to eradicate malaria it will be necessary to know how, when and where to attack hypnozoites.
Due to the lack of experimental systems hypnozoites are almost completely undefined and mechanisms of their formation and/or reactivation are unknown. The primate parasite P. cynomolgi (Pcy) offers a model for dormancy and relapse but large-scale experiments in non-human primates, e.g. to identify new drugs, are restricted for ethical and financial reasons. To bridge this gap we have generated human and simian liver chimeric mice, which are powerful tools to Pv and Pcy in their native environment. We will profile Pv and Pcy liver stages and their host cells using transcriptomic and/or proteomic approaches. Molecular signatures of malarial dormancy will be critical for identifying putative therapeutic intervention points.
Generation of humanized for the study of human infectious disease
"Humanized" mice are versatile tools in the investigation of human disease. These are amenable small animal models transplanted with human cells or tissues (and/or equipped with human transgenes) that may be ideally suited for direct investigation of human infectious agents. Successful engraftment depends on avoiding rejection and maximizing tissue function, ensured by correct localization and appropriate tissue support by host factors. Despite the challenges, humanized mouse technology has made rapid progress over the last few years and it is now possible to achieve high levels of human chimerism in various host organs/tissues, particularly the immune system and liver. Such humanized mice provide a new opportunity to perform pre-clinical studies of intractable human pathogens. Despite their promise as challenge models, immune responses to infection remain suboptimal in humanized mice. In order to improve immune function, we employ a combination strategies including enhancing the ablation of endogenous mouse subsets to create "space" for human cells, providing exogenous cytokines to overcome impaired biological cross-reactivity between mouse and human, counteracting active graft destruction, and expressing human MHC molecules to ensure proper T cell education and homeostasis.
Ploss A. (2014) Mouse models for human infectious diseases. J Immunol Methods. Jul 11. [Epub ahead of print]
Billerbeck E, Labitt RN, Vega K, Frias-Staheli N, Dorner M, Xiao J, Rice CM, Ploss A. (2014) Insufficient IL-12 signaling favors differentiation of human CD4+ and CD8+ T cells into GATA-3+ and GATA-3+ T-bet+ subsets in humanized mice. Immunology. Apr 25. [Epub ahead of print]
von Schaewen M, Ploss A. (2014) Murine models of hepatitis C: What can we look forward to? Antiviral Res. 104:15-22. Pubmed
Horwitz JA, Halper-Stromberg A, Mouquet H,...Ploss A,...Nussenzweig MC. (2013) HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc Natl Acad Sci. 110: 16538-43. Pubmed
Anggakusuma, Colpitts CC, Schang LM,...Ploss A,...Steinmann E. (2013) Turmeric curcumin inhibits entry of all hepatitis C virus genotypes into human liver cells. Gut. 63: 1137-49. Pubmed
Dorner M, Horwitz JA, Donovan BM,...Ploss A. (2013) Completion of the entire hepatitis C virus life cycle in genetically humanized mice. Nature. 501: 237-41. Pubmed
Billerbeck E, Horwitz JA, Labitt RN,...Ploss A. (2013) Characterization of human antiviral adaptive immune responses during hepatotropic virus infection in HLA-transgenic human immune system mice. J Immunol. 191: 1753-64. Pubmed
Gruell H, Bournazos S, Ravetch JV, Ploss A, Nussenzweig MC, Pietzsch J. (2013) Antibody and antiretroviral pre-exposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol. 87: 8535-44. Pubmed
Vogt A, Scull MA, Friling T,...Ploss A. (2013) Recapitulation of the hepatitis C virus life-cycle in engineered murine cell lines. Virology. 444: 1-11. Pubmed
Guermonprez P, Helft J, Claser C,...Ploss A,...Nussenzweig MC. (2013) Inflammatory Flt3l is essential to mobilize dendritic cells and for T cell responses during Plasmodium infection. Nat Med. 19: 730-38. Pubmed
Horwitz JA, Dorner M, Friling T,...Ploss A. (2013) Expression of heterologous proteins flanked by NS3-4A cleavage sites within the hepatitis C virus polyprotein. Virology. 439: 23-33. Pubmed
Billerbeck E, de Jong Y, Dorner M, de la Fuente C, Ploss A. (2013) Animal models for hepatitis C. Animal models for hepatitis C. Curr Top Microbiol Immunol. 369: 49-86. Pubmed
Shi C, Ploss A. (2013) Hepatitis C virus vaccines in the era of new direct-acting antivirals. Expert Rev Gastroenterol Hepatol. 7: 171-85. Pubmed
Sandmann L, Ploss A. (2013) Barriers of hepatitis C virus interspecies transmission. Virology. 435: 70-80. Pubmed
Dorner M, Rice CM, Ploss A. (2013) Study of hepatitis C virus entry in genetically humanized mice. Methods. 59: 249-57. Pubmed
Klein F, Halper-Stromberg A, Horwitz JA,...Ploss A, Nussenzweig MC. (2012) HIV therapy by a combination of broadly neutralizing antibodies in humanized mice, Nature. 492: 118-22. Pubmed
Pietzsch J, Gruell H, Bournazos S,...Ploss A, Nussenzweig MC. (2012) A mouse model for HIV entry. Proc Natl Acad Sci. 109: 15859-64. Pubmed
Vaughan AM, Mikolajczak SA, Wilson EM,...Ploss A, Kappe SH. (2012) Complete plasmodium falciparum liver-stage development in liver-chimeric mice. J Clin Invest. 122: 3618-28. Pubmed
Schoggins JW, Dorner M, Feulner M...Ploss A, Rice CM. (2012) Development of fully infectious dengue reporter viruses for bioluminescent imaging and high throughput screening, Proc Natl Acad Sci. 109: 14610-15. Pubmed
Vaughan AM, Kappe SH, Ploss A, Mikolajczak SA. (2012) Development of humanized mouse models to study human malaria parasite infection. Future Microbiol. 7: 657-65. Pubmed
Ploss A, Dubuisson J. (2012) New advances in the molecular biology of hepatitis C virus infection: towards the identification of new treatment targets, Gut. 61 Suppl 1: i25-35. Pubmed
Giang E, Dorner M, Prentoe JC,...Ploss A, Burton DR, Law M. (2012) Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus. Proc Natl Acad Sci. 109: 6205-10. Pubmed
Ploss A, Evans M. (2012) Hepatitis C virus entry. Curr Opin Virol. 2: 14-19. Pubmed
Meng X, Schoggins J, Rose L,...Ploss A,...Xiang Y. (2012) C7L family of poxvirus host range genes inhibits antiviral activities induced by type I interferons and interferon regulatory factor 1. J Virology. 86: 4538-47. Pubmed
Schwartz RE, Trehan K, Andrus L, Ploss A,...Bhatia SN. (2012) Modeling hepatitis C virus infection using human induced pluripotent stem cells. Proc Natl Acad Sci. 109: 2544-48. Pubmed
Scull MA, Ploss A. (2012) Exiting from uncharted territory: Hepatitis C virus assembles in mouse cell lines. Hepatology. 55: 645-48. Pubmed
Dorner M, Ploss A. (2011) Deconstructing hepatitis C virus infection in small animal models. (2011) Ann N Y Acad Sci. 1245: 59-62. Pubmed
Marukian S, Andrus L, Sheahan TP,...Ploss A,...Dustin LB. (2011) Hepatitis C virus induces interferon-λ and interferon-stimulated genes in primary liver cultures. Hepatology. 54: 1913-23. Pubmed
Andrus L, Marukian S, Jones CT,...Ploss A,...Rice CM. (2011) Expression of paramyxovirus V proteins promotes replication and spread of hepatitis C virus in cultures of primary human fetal liver cells. Hepatology. 54: 1901-12. Pubmed
Dorner M, Horwitz JA, Robbins J,...Ploss A. (2011) A genetically humanized mouse model for hepatitis C virus infection. Nature. 474: 208-11. Pubmed
Washburn ML, Bility MT, Kovalev GI,...Ploss A,...Su L. (2011) A novel humanized mouse model with a human immune system and human liver supports Hepatitis C virus infection, immune responses, and hepatopathogenesis. Gastroenterology. 40: 1334-44. Pubmed
Billerbeck E, Barry WT, Mu K, Dorner M, Rice CM, Ploss A. (2011) Development of human CD4+FoxP3+ regulatory T cells in human stem cell factor, GM-CSF and interleukin 3 expressing NOD SCID IL2RγNULL humanized mice. Blood. 117: 3076-86. Pubmed
De Jong YP, Rice CM, Ploss A. (2010) Evaluation of combination therapy against hepatitis C virus infection in human liver chimeric mice. J. Hepatol. 54: 848-50. Pubmed
Gerold G, Rice CM, Ploss A. (2010) Teaching new tricks to an old foe: murinizing Hepatitis C virus. Hepatology. 52: 2233-36. Pubmed
Sheahan T, Jones CT, Ploss A. (2010) Advances and challenges in studying hepatitis C virus in its native environment, Expert Rev Gastroenterol Hepatol. 4: 541-50. Pubmed
Kohaar I, Ploss A, Korol E,...Prokunina-Olsson L. (2010) Splicing diversity of human OCLN gene and its biological significance for hepatitis C virus (HCV) entry. J Virol. 84: 6987-94. Pubmed
De Jong YP, Rice CM, Ploss A. (2010) New horizons for studying human hepatotropic infections. J Clin Invest. 120: 650-53. Pubmed
Jones CT, Catanese MT, Law LMJ,...Ploss A,...Rice CM. (2010) Real-time imaging of hepatitis C virus infection using a fluorescent cell-based reporter system. Nat Biotechnol. 28: 167-71. Pubmed
Ploss A, Khetani SK, Jones CT,...Bhatia SN. (2010) Persistent hepatitis C virus infection in microscale primary human hepatocyte cultures. Proc Natl Acad Sci. 107: 3141-45. Pubmed
Akondy RS, Monson ND, Miller JD,...Ploss A,...Ahmed R. (2009) The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response. J Immunol. 183: 7919-30. Pubmed
Ploss A, Rice CM. (2009) Towards a small model for Hepatitis C. EMBO Rep. 10: 1220-27. Pubmed
Legrand N, Ploss A, Balling R,...Ziegler P. (2009) Humanized mice for modeling human infectious disease: challenges, progress, and outlook. Cell Host Microbe. 6: 5-9. Pubmed
Strowig T, Gurer C, Ploss A,...Münz C. (2009) Priming of protective T cell responses against virus-induced tumors in mice with human immune system components. J Exp Med. 206: 1423-34. Pubmed
Ploss A, Evans MJ, Gaysinskaya VA,...Rice CM. (2009) Human occludin is a hepatitis C virus entry factor required for infection of mouse cells, Nature. 457: 882-86. Pubmed
Biswas PS, Pedicord V, Ploss A, Menet E, Leiner I, Pamer EG. (2007) Pathogen-specific CD8 T cell responses are directly inhibited by IL-10. J Immunol. 179: 4520-28. Pubmed
Lindenbach BD, Meuleman P, Ploss A,...Rice CM. (2006) Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. Proc Natl Acad Sci. 103: 3805-09. Pubmed
Ploss A, Leiner I, Pamer EG. (2005) Distinct regulation of H2-M3 restricted memory T cell responses in lymph node and spleen. J Immunol. 175: 5998-6005. Pubmed
Ploss A, Tran A, Menet E, Leiner I, Pamer EG. (2005) Cross-recognition of N-formyl methionine peptides is a general characteristic of H2-M3 restricted CD8+ T cells. Infect Immun. 73: 4423-26. Pubmed
Dao T, Guo D, Ploss A,...Sant'Angelo DB. (2004) Development of CD1d-restricted NKT cells in the mouse thymus. Eur J Immunol. 34: 3542-52. Pubmed
Wong P, Lara-Tejero M, Ploss A, Leiner I, Pamer EG. (2004) Rapid development of T cell memory. J Immunol. 172: 7239-45. Pubmed
Ploss A, Lauvau G, Contos B,...Pamer EG. (2003) Promiscuity of MHC class Ib restricted T cell responses. J Immunol. 171: 5948-55. Pubmed
Kerksiek KM, Ploss A, Leiner I, Busch DH, Pamer EG. (2003) H2-M3 restricted T cells respond to secondary antigen exposure. J Immunol. 170: 1862-69. Pubmed
Reuss FU, Heber R, Ploss A, Berdel B. (2001) Amphotropic murine leukemia virus replication in human mammary epithelial cells and the formation of cytomegalovirus-promoter recombinants. Virology. 291: 91-100. Pubmed
Ploss A. (2012) Hepatitis C virus and use of reverse genetics in drug design, in A. Bridgen (Ed.) Chapter 3: Reverse Genetics of RNA Viruses: Applications and Perspectives, pages 64-90, Wiley-Blackwell
Ploss A, Pamer EG. (2005) Immunologic Memory. In: Meyers, R.A., ed. Encyclopedia of Molecular Cell Biology and Molecular Medicine, WILEY-VCH Verlag GmbH & Co., Weinheim. p. 383
Ploss A, Pamer EG. (2004) Memory, in S.H.E. Kaufmann (Ed.) Novel Vaccination Strategies, WILEY-VCH, Weinheim, New York, pp.73